OTLK
Outlook Therapeutics, Inc.
Price Chart
Latest Quote
$1.83
+0.25 (+15.82%)
Current Price
| Previous Close | $1.58 |
| Open | $1.58 |
| Day High | $1.88 |
| Day Low | $1.47 |
| Volume | 17,619,765 |
Stock Information
| Shares Outstanding | 148.59M |
| Total Debt | $27.19M |
| Cash Equivalents | $7.75M |
| Revenue | $333K |
| Net Income | $-60.96M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $271.91M |
| EPS (TTM) | $-1.13 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $240.62M |
| Sales | $333K |
| Income | $-60.96M |
| Book/sh | $-0.28 |
| Cash/sh | $0.05 |
| Employees | 17 |
Financial Ratios
| Quick Ratio | 0.27 |
| Current Ratio | 0.54 |
Returns & Margins
| ROA | -184.82% |
| Operating Margin | -11006.82% |
Ownership
| Insider Ownership | 17.42% |
| Institutional Ownership | 6.92% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.32 |
| P/S | 816.21 |
| P/B | -6.61 |
Analyst Data
| Recommendation | buy |
| Target Price | $5.50 |
Technical Indicators
| SMA20 | $0.96 |
| SMA50 | $0.54 |
| SMA200 | $0.88 |
| RSI | 82.40 |
| ATR | 0.2024 |
| Shares Float | 96.40M |
| Short Float | 11.95% |
| Short Ratio | 0.53 |
| Volatility | 0.98 |
| Rel Volume | 0.38 |
Performance History
| Week | +50.00% |
| Month | +570.33% |
| Quarter | +421.37% |
| 6 Months | -19.38% |
| YTD | +177.27% |
| Year | +8.93% |
| 3 Years | -94.55% |
| 5 Years | -96.47% |
| 10 Years | -99.68% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $1.83 | 17,780,300 |
| 2026-06-18 | $1.58 | 20,623,200 |
| 2026-06-17 | $1.65 | 24,485,100 |
| 2026-06-16 | $1.57 | 42,831,600 |
| 2026-06-15 | $1.16 | 23,475,000 |
| 2026-06-12 | $1.22 | 37,697,100 |
| 2026-06-11 | $1.10 | 43,930,100 |
| 2026-06-10 | $0.89 | 23,161,000 |
| 2026-06-09 | $0.70 | 7,587,200 |
| 2026-06-08 | $0.72 | 8,661,600 |
| 2026-06-05 | $0.78 | 12,110,700 |
| 2026-06-04 | $0.80 | 11,075,500 |
| 2026-06-03 | $0.81 | 11,054,900 |
| 2026-06-02 | $0.81 | 18,805,000 |
| 2026-06-01 | $0.84 | 44,169,600 |
| 2026-05-29 | $0.73 | 31,623,100 |
| 2026-05-28 | $0.74 | 107,389,800 |
| 2026-05-27 | $0.59 | 84,216,700 |
| 2026-05-26 | $0.40 | 346,266,300 |
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
đ° Latest News
OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review
Zacks âĸ 2026-06-17T14:20:00Z
Outlook Therapeutics (OTLK) Stock After FDA Review Win Is The Valuation Case Already Priced In
Simply Wall St. âĸ 2026-06-16T20:08:54Z
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision
Stocktwits âĸ 2026-06-16T17:47:26Z
Why Outlook Therapeutics (OTLK) Is Up 57.1% After FDA Validates LYTENAVA Efficacy and BLA Resubmission
Simply Wall St. âĸ 2026-06-14T13:08:32Z
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal
Stocktwits âĸ 2026-06-01T17:05:59Z
OTLK Stock Rocket Nearly 140%: Lytenava Dispute Resolution With FDA Pushes Stock On Track For Best Week On Record
Stocktwits âĸ 2026-05-28T17:38:14Z
Why RDW, TE, OTLK Stocks Posted Double-Digit Gains On Tuesday
Stocktwits âĸ 2026-05-27T05:10:40Z
OTLK Stock Surges Over 50% Pre-Market, Breaches Key Technical Milestone â Whatâs Behind This Massive Rally?
Stocktwits âĸ 2026-05-26T13:08:00Z
Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-15T21:25:01Z
Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-02-17T14:15:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,356,330 | $0 | - | - |
| Cost Of Revenue | $1,356,330 | $0 | - | - |
| Total Revenue | $1,413,535 | $0 | $0 | $0 |
| Operating Revenue | $1,413,535 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $283,128 | $3,156,964 | $2,531,228 | $1,487,456 |
| Total Expenses | $68,475,201 | $71,703,235 | $53,126,382 | $63,070,753 |
| Other Income Expense | $3,278,364 | $-1,409,865 | $-4,293,738 | $-1,491,255 |
| Other Non Operating Income Expenses | $-39,596,460 | $-39,947,165 | $-3,756,000 | $-882,903 |
| Net Non Operating Interest Income Expense | $-193,390 | $-2,250,814 | $-1,559,748 | $-1,487,456 |
| Interest Expense Non Operating | $283,128 | $3,156,964 | $2,531,228 | $1,487,456 |
| Operating Expense | $67,118,871 | $71,703,235 | $53,126,382 | $63,070,753 |
| General And Administrative Expense | $39,938,231 | $29,940,188 | $26,673,440 | $20,739,897 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-62,424,863 | $-75,366,714 | $-58,982,668 | $-66,052,264 |
| Net Interest Income | $-193,390 | $-2,250,814 | $-1,559,748 | $-1,487,456 |
| Interest Income | $89,738 | $906,150 | $971,480 | - |
| Normalized Income | $-104,408,314 | $-114,004,756 | $-58,455,928 | $-65,492,642 |
| Net Income From Continuing And Discontinued Operation | $-62,424,863 | $-75,366,714 | $-58,982,668 | $-66,052,264 |
| Total Operating Income As Reported | $-67,061,666 | $-71,703,235 | $-53,126,382 | $-63,070,753 |
| Net Income Common Stockholders | $-62,424,863 | $-75,366,714 | $-58,982,668 | $-66,052,264 |
| Net Income | $-62,424,863 | $-75,366,714 | $-58,982,668 | $-66,052,264 |
| Net Income Including Noncontrolling Interests | $-62,424,863 | $-75,366,714 | $-58,982,668 | $-66,052,264 |
| Net Income Continuous Operations | $-62,424,863 | $-75,366,714 | $-58,982,668 | $-66,052,264 |
| Pretax Income | $-63,976,692 | $-75,363,914 | $-58,979,868 | $-66,049,464 |
| Earnings From Equity Interest | $-141,007 | $-100,742 | $-10,998 | $-48,730 |
| Interest Income Non Operating | $89,738 | $906,150 | $971,480 | - |
| Operating Income | $-67,061,666 | $-71,703,235 | $-53,126,382 | $-63,070,753 |
| Gross Profit | $57,205 | $0 | - | - |
| Special Income Charges | - | $0 | $-577,659 | $-1,025,402 |
| Per Share | ||||
| Diluted EPS | $-1.79 | $-4.06 | $-4.80 | $-6.20 |
| Basic EPS | $-1.79 | $-4.06 | $-4.80 | $-6.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $1,032,380 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-106,592,343 | $-110,731,133 | $-55,877,712 | $-63,797,692 |
| Total Unusual Items | $43,015,831 | $38,638,042 | $-526,740 | $-559,622 |
| Total Unusual Items Excluding Goodwill | $43,015,831 | $38,638,042 | $-526,740 | $-559,622 |
| Reconciled Depreciation | $117,052 | $113,859 | $44,188 | $204,694 |
| EBITDA (Bullshit earnings) | $-63,576,512 | $-72,093,091 | $-56,404,452 | $-64,357,314 |
| EBIT | $-63,693,564 | $-72,206,950 | $-56,448,640 | $-64,562,008 |
| Diluted Average Shares | $34,796,000 | $18,549,000 | $12,508,850 | $10,603,973 |
| Basic Average Shares | $34,796,000 | $18,549,000 | $12,508,850 | $10,603,973 |
| Diluted NI Availto Com Stockholders | $-62,424,863 | $-75,366,714 | $-58,982,668 | $-66,052,264 |
| Tax Provision | $-1,551,829 | $2,800 | $2,800 | $2,800 |
| Gain On Sale Of Security | $43,015,831 | $38,638,042 | $50,919 | $465,780 |
| Research And Development | $27,180,640 | $41,763,047 | $26,452,942 | $42,330,856 |
| Selling General And Administration | $39,938,231 | $29,940,188 | $26,673,440 | $20,739,897 |
| Other Gand A | $23,280,862 | $19,054,820 | $17,746,572 | $11,617,640 |
| Salaries And Wages | $16,657,369 | $10,885,368 | $8,926,868 | $9,122,257 |
| Other Special Charges | - | - | $577,659 | $1,025,402 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
| Impairment Of Capital Assets | - | - | - | - |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-32,187,661 | $-73,076,510 | $-14,437,777 | $8,736,571 |
| Total Assets | $18,584,183 | $28,823,154 | $32,300,601 | $28,527,751 |
| Total Non Current Assets | $1,195,214 | $1,407,118 | $1,321,403 | $1,007,305 |
| Other Non Current Assets | $417,523 | $439,283 | $501,299 | $132,015 |
| Current Assets | $17,388,969 | $27,416,036 | $30,979,198 | $27,520,446 |
| Other Current Assets | $4,476,549 | $12,488,498 | $7,587,216 | $10,123,634 |
| Inventory | $3,338,404 | $0 | - | - |
| Receivables | $1,490,931 | $0 | - | - |
| Accounts Receivable | $1,490,931 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $8,083,085 | $14,927,538 | $23,391,982 | $17,396,812 |
| Cash And Cash Equivalents | $8,083,085 | $14,927,538 | $23,391,982 | $17,396,812 |
| Prepaid Assets | - | - | - | $10,123,634 |
| Debt | ||||
| Net Debt | $21,863,915 | $14,512,462 | $12,159,018 | - |
| Total Debt | $30,194,698 | $29,737,829 | $35,555,267 | $10,958,028 |
| Long Term Debt And Capital Lease Obligation | $188,801 | $246,922 | $0 | $4,267 |
| Current Debt And Capital Lease Obligation | $30,005,897 | $29,490,907 | $35,555,267 | $10,953,761 |
| Current Debt | $29,947,000 | $29,440,000 | $35,551,000 | $10,915,015 |
| Other Current Borrowings | $29,947,000 | $29,440,000 | $35,551,000 | $10,915,015 |
| Long Term Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $50,771,844 | $101,899,664 | $46,738,378 | $19,791,180 |
| Total Non Current Liabilities Net Minority Interest | $4,957,239 | $59,345,935 | $6,219 | $61,405 |
| Derivative Product Liabilities | $4,768,438 | $59,099,013 | $6,219 | $57,138 |
| Current Liabilities | $45,814,605 | $42,553,729 | $46,732,159 | $19,729,775 |
| Payables And Accrued Expenses | $12,780,824 | $12,049,860 | $10,256,922 | $6,799,762 |
| Payables | $10,494,388 | $9,825,354 | $8,431,152 | $5,348,114 |
| Total Tax Payable | $302,000 | $1,856,629 | $1,856,629 | $1,856,629 |
| Income Tax Payable | $302,000 | $1,856,629 | $1,856,629 | $1,856,629 |
| Accounts Payable | $10,192,388 | $7,968,725 | $6,574,523 | $3,491,485 |
| Interest Payable | - | - | - | $0 |
| Current Notes Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $-32,187,661 | $-73,076,510 | $-14,437,777 | $8,736,571 |
| Total Equity Gross Minority Interest | $-32,187,661 | $-73,076,510 | $-14,437,777 | $8,736,571 |
| Stockholders Equity | $-32,187,661 | $-73,076,510 | $-14,437,777 | $8,736,571 |
| Retained Earnings | $-605,709,763 | $-543,284,900 | $-467,918,186 | $-408,935,518 |
| Long Term Equity Investment | $552,183 | $693,190 | $793,932 | $804,930 |
| Investments In Other Ventures Under Equity Method | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $53,887,233 | $23,905,635 | $13,012,875 | $11,365,528 |
| Share Issued | $53,887,233 | $23,905,635 | $13,012,875 | $11,365,528 |
| Tangible Book Value | $-32,187,661 | $-73,076,510 | $-14,437,777 | $8,736,571 |
| Invested Capital | $-2,240,661 | $-43,636,510 | $21,113,223 | $19,651,586 |
| Working Capital | $-28,425,636 | $-15,137,693 | $-15,752,961 | $7,790,671 |
| Capital Lease Obligations | $247,698 | $297,829 | $4,267 | $43,013 |
| Total Capitalization | $-32,187,661 | $-73,076,510 | $-14,437,777 | $8,736,571 |
| Additional Paid In Capital | $572,983,229 | $469,969,333 | $453,350,281 | $415,398,984 |
| Capital Stock | $538,873 | $239,057 | $130,128 | $2,273,105 |
| Common Stock | $538,873 | $239,057 | $130,128 | $2,273,105 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $188,801 | $246,922 | $0 | $4,267 |
| Current Capital Lease Obligation | $58,897 | $50,907 | $4,267 | $38,746 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,027,884 | $1,012,962 | $919,970 | $1,976,252 |
| Current Accrued Expenses | $2,286,436 | $2,224,506 | $1,825,770 | $1,451,648 |
| Investments And Advances | $552,183 | $693,190 | $793,932 | $804,930 |
| Investmentsin Joint Venturesat Cost | $552,183 | $693,190 | $793,932 | $804,930 |
| Net PPE | $225,508 | $274,645 | $26,172 | $70,360 |
| Gross PPE | $225,508 | $274,645 | $26,172 | $70,360 |
| Other Properties | $225,508 | $274,645 | $26,172 | $70,360 |
| Finished Goods | $29,626 | - | - | - |
| Work In Process | $958,539 | - | - | - |
| Raw Materials | $2,350,239 | - | - | - |
| Accumulated Depreciation | - | - | - | $-1,067,351 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-51,829,437 | $-68,793,858 | $-42,973,398 | $-56,674,559 |
| Operating Activities | ||||
| Operating Cash Flow | $-51,829,437 | $-68,793,858 | $-42,973,398 | $-56,674,559 |
| Cash Flow From Continuing Operating Activities | $-51,829,437 | $-68,793,858 | $-42,973,398 | $-56,674,559 |
| Operating Gains Losses | $-42,874,824 | $-1,047,288 | $537,738 | $608,352 |
| Investing Activities | ||||
| Investing Cash Flow | - | - | - | - |
| Cash Flow From Continuing Investing Activities | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $25,396,398 | $60,333,681 | $30,024,213 | $62,307,307 |
| Financing Cash Flow | $44,984,984 | $60,329,414 | $48,968,568 | $59,594,047 |
| Cash Flow From Continuing Financing Activities | $44,984,984 | $60,329,414 | $48,968,568 | $59,594,047 |
| Net Common Stock Issuance | $25,396,398 | $60,333,681 | $30,024,213 | $62,307,307 |
| Common Stock Issuance | $25,396,398 | $60,333,681 | $30,024,213 | $62,307,307 |
| Net Other Financing Charges | - | - | $-823,894 | $-600,000 |
| Other | ||||
| Repayment Of Debt | $-36,142,586 | $-4,267 | $-10,231,751 | $-12,319,110 |
| Issuance Of Debt | $33,100,000 | $0 | $30,000,000 | $10,000,000 |
| Interest Paid Supplemental Data | $0 | $475,000 | $1,160,008 | $1,556,691 |
| End Cash Position | $8,083,085 | $14,927,538 | $23,391,982 | $17,396,812 |
| Beginning Cash Position | $14,927,538 | $23,391,982 | $17,396,812 | $14,477,324 |
| Changes In Cash | $-6,844,453 | $-8,464,444 | $5,995,170 | $2,919,488 |
| Proceeds From Stock Option Exercised | $22,631,172 | $0 | $0 | $205,850 |
| Net Issuance Payments Of Debt | $-3,042,586 | $-4,267 | $19,768,249 | $-2,319,110 |
| Net Long Term Debt Issuance | $-3,042,586 | $-4,267 | $19,768,249 | $-2,319,110 |
| Long Term Debt Payments | $-36,142,586 | $-4,267 | $-10,231,751 | $-12,319,110 |
| Long Term Debt Issuance | $33,100,000 | $0 | $30,000,000 | $10,000,000 |
| Change In Working Capital | $4,858,851 | $-3,017,839 | $4,753,104 | $-1,684,388 |
| Change In Other Current Liabilities | $-50,131 | $3,413 | $-26,995 | $-42,854 |
| Change In Other Current Assets | $-95,247 | $-5,900 | $-208,203 | $0 |
| Change In Payables And Accrued Expense | $1,821,615 | $1,885,930 | $2,371,377 | $1,451,277 |
| Change In Accrued Expense | $1,710,195 | $491,728 | $-711,661 | $156,141 |
| Change In Payable | $111,420 | $1,394,202 | $3,083,038 | $1,295,136 |
| Change In Account Payable | $1,666,049 | $1,394,202 | $3,083,038 | $1,295,136 |
| Change In Tax Payable | $-1,554,629 | $0 | - | - |
| Change In Income Tax Payable | $-1,554,629 | $0 | - | - |
| Change In Prepaid Assets | $8,011,949 | $-4,901,282 | $2,616,925 | $-3,092,811 |
| Change In Inventory | $-3,338,404 | $0 | - | - |
| Change In Receivables | $-1,490,931 | $0 | - | - |
| Changes In Account Receivables | $-1,490,931 | $0 | - | - |
| Other Non Cash Items | $33,521,874 | $2,681,847 | $1,371,221 | $1,655,340 |
| Stock Based Compensation | $8,897,887 | $5,385,124 | $5,547,019 | $7,710,804 |
| Unrealized Gain Loss On Investment Securities | $6,074,586 | $2,457,153 | $3,756,000 | $882,903 |
| Depreciation Amortization Depletion | $117,052 | $113,859 | $44,188 | $204,694 |
| Depreciation And Amortization | $117,052 | $113,859 | $44,188 | $204,694 |
| Earnings Losses From Equity Investments | $141,007 | $100,742 | $10,998 | $48,730 |
| Gain Loss On Investment Securities | $-43,015,831 | $-1,148,030 | $-50,919 | $-465,780 |
| Net Income From Continuing Operations | $-62,424,863 | $-75,366,714 | $-58,982,668 | $-66,052,264 |
| Net Business Purchase And Sale | - | - | - | - |
| Purchase Of Business | - | - | - | - |
| Asset Impairment Charge | - | - | - | - |
Fetched: 2026-06-22